The current recommended drugs and strategies for the treatment of coronavirus disease (COVID-19)
M Sheikhpour - Therapeutics and clinical risk management, 2020 - Taylor & Francis
Background The coronavirus 2019 (COVID-19) has been known as a pandemic disease by
the World Health Organization (WHO) worldwide. The drugs currently used for treatment of …
the World Health Organization (WHO) worldwide. The drugs currently used for treatment of …
Mitochondrial hijacking: A potential mechanism for SARS-CoV-2 to impair female fertility
J Sun, Q Liu, X Zhang, S Dun, L Liu - Medical hypotheses, 2022 - Elsevier
As well as causing respiratory lesions, the multi-organ complications caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are also well known. Combined …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are also well known. Combined …
[PDF][PDF] Potential role of micro RNAs in the treatment of COVID-19 (SARS-CoV-2 virus). J RNA Genom 2022; S03 (001): 1-7. 2 J RNA Genom 2022 Volume S03 Issue …
COVID-19 firstly erupted in China in December 2019 as an epidemic that led to a global
pandemic within a short span of time. Evaluating and examining patients and after …
pandemic within a short span of time. Evaluating and examining patients and after …
Generierung monoklonaler Antikörper gegen SARS-CoV-2 und ZIKV durch In-Vitro-Immunisierung mittels zellpermeabler virusähnlicher Partikel als Antigenträger
Y Husria - 2022 - refubium.fu-berlin.de
SARS-CoV-2 und ZIKV sind zwei neu auftretende Krankheitserreger. Ein wesentliches
Werkzeug für die Charakterisierung des viralen Lebenszyklus sind Antikörper. Monoklonale …
Werkzeug für die Charakterisierung des viralen Lebenszyklus sind Antikörper. Monoklonale …